McClain KL - Search Results

1

Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.

Chakraborty R, Burke TM, Hampton OA, Zinn DJ, Lim KP, Abhyankar H, Scull B, Kumar V, Kakkar N, Wheeler DA, Roy A, Poulikakos PI, Merad M, McClain KL, Parsons DW, Allen CE. Chakraborty R, et al. Among authors: mcclain kl. Blood. 2016 Nov 24;128(21):2533-2537. doi: 10.1182/blood-2016-08-733790. Epub 2016 Oct 11. Blood. 2016. PMID: 27729324 Free PMC article.

2

Langerhans cell histiocytosis: lack of a viral etiology.

McClain K, Jin H, Gresik V, Favara B. McClain K, et al. Am J Hematol. 1994 Sep;47(1):16-20. doi: 10.1002/ajh.2830470104. Am J Hematol. 1994. PMID: 8042610

3

Viruses and Langerhans cell histiocytosis: is there a link?

McClain K, Weiss RA. McClain K, et al. Br J Cancer Suppl. 1994 Sep;23:S34-6. Br J Cancer Suppl. 1994. PMID: 8075003 Free PMC article. Review.

4

DNA polymorphisms and mutations of the tumor necrosis factor-alpha (TNF-alpha) promoter in Langerhans cell histiocytosis (LCH).

Wu WS, McClain KL. Wu WS, et al. Among authors: mcclain kl. J Interferon Cytokine Res. 1997 Oct;17(10):631-5. doi: 10.1089/jir.1997.17.631. J Interferon Cytokine Res. 1997. PMID: 9355965 Clinical Trial.

5

Need for a cooperative study: Pulmonary Langerhans cell histiocytosis and its management in adults.

McClain KL, Gonzalez JM, Jonkers R, De Juli E, Egeler M. McClain KL, et al. Med Pediatr Oncol. 2002 Jul;39(1):35-9. doi: 10.1002/mpo.10064. Med Pediatr Oncol. 2002. PMID: 12116077 Review.

6

Adult Langerhans cell histiocytosis limited to the skin.

Singh A, Prieto VG, Czelusta A, McClain KL, Duvic M. Singh A, et al. Among authors: mcclain kl. Dermatology. 2003;207(2):157-61. doi: 10.1159/000071786. Dermatology. 2003. PMID: 12920365 Review.

7

Langerhans cell histiocytosis patients have HLA Cw7 and DR4 types associated with specific clinical presentations and no increased frequency in polymorphisms of the tumor necrosis factor alpha promoter.

McClain KL, Laud P, Wu WS, Pollack MS. McClain KL, et al. Med Pediatr Oncol. 2003 Dec;41(6):502-7. doi: 10.1002/mpo.10366. Med Pediatr Oncol. 2003. PMID: 14595706

8

Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.

Haupt R, Nanduri V, Calevo MG, Bernstrand C, Braier JL, Broadbent V, Rey G, McClain KL, Janka-Schaub G, Egeler RM. Haupt R, et al. Among authors: mcclain kl. Pediatr Blood Cancer. 2004 May;42(5):438-44. doi: 10.1002/pbc.20021. Pediatr Blood Cancer. 2004. PMID: 15049016

9

Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.

Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R. Jordan MB, et al. Among authors: mcclain kl. Pediatr Blood Cancer. 2005 Mar;44(3):251-4. doi: 10.1002/pbc.20181. Pediatr Blood Cancer. 2005. PMID: 15390358

10

Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis.

Rolland A, Guyon L, Gill M, Cai YH, Banchereau J, McClain K, Palucka AK. Rolland A, et al. J Immunol. 2005 Mar 1;174(5):3067-71. doi: 10.4049/jimmunol.174.5.3067. J Immunol. 2005. PMID: 15728521

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

212 results

Search Page